It will be a time when there’s a lot of hope, but a real normal will still be months away. Akebia Therapeutics has a twelve month low of $2.34 and a twelve month high of $13.71. Learn everything you need to know about successful options trading with this three-part video course. They issued a "buy" rating and a $18.00 price target for the company. Jeff Brown just released a new research report. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. After each calculation the program assigns a Buy, Sell, or Hold value with the study, depending on where the price lies in reference to the common interpretation of the study. Akebia Therapeutics (AKBA) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). Its lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients. The past year's Accounts Payable Turnover was at 7.31. Export data to Excel for your own analysis. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Users should not base their investment decision upon "StockInvest.us". Limited Time Only. Akebia Therapeutics Inc. () Stock Market info Recommendations: Buy or sell Akebia Therapeutics stock? Great West Life Assurance Co. Can now owns 7,428 shares of the biopharmaceutical company's stock valued at $100,000 after buying an additional 2,962 shares during the last quarter. Great West Life Assurance Co. Can boosted its position in Akebia Therapeutics by 66.3% in the 2nd quarter. featured in The Global Fintech Index 2020 as the top Fintech company of the country. 100% FREE. JPMorgan Chase & Co. cut Akebia Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Thursday, September 3rd. If the lower trend floor at $3.41 is broken, it will firstly indicate a slower rate of rising, but may also be an early warning for a trend shift. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. Akebia Therapeutics finds support from accumulated volume at $3.47 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Buy, Sell Or Hold Akebia Therapeutics, Inc. (NASDAQ:AKBA) At $2.73? Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. PNC Financial Services Group Inc. bought a new position in Akebia Therapeutics in the 2nd quarter valued at $28,000. So shareholders might well want to know whether insiders have been buying or selling shares in Akebia Therapeutics, Inc. (NASDAQ:AKBA). AKBA closed up 8.11 percent on Tuesday, March 9, 2021, on 64 percent of normal volume. On a fall, the stock will find some support from the short-term average at $3.50. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. 5 of the analysts rate the stock as a “Buy”. Opinions of the stock are interesting as 5 analysts out of 7 who provided ratings for Akebia Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 1 as “sell.” Valeo Financial Advisors LLC now owns 8,245 shares of the biopharmaceutical company's stock valued at $112,000 after buying an additional 800 shares during the last quarter. Over the last 30 days, this security got 2 buy, 0 sell and 0 hold ratings. To see all exchange delays and terms of use please see disclaimer. Shares of Akebia Therapeutics (NASDAQ:AKBA) are plunging today, down 72.3% as of 11:15 a.m. EDT, after the company announced results from … The business had revenue of $90.14 million during the quarter, compared to analysts' expectations of $76.24 million. Get daily stock ideas top-performing Wall Street analysts. This is why we are offering FREE 14 days TRIAL SUBSCRIPTIONS with no further commitments. During the day the stock fluctuated 2.51% from a day low at $3.59 to a day high of $3.68. The stock has a market capitalization of $346.83 million, a PE ratio of -0.81 and a beta of 1.66. What should you do? The stock has a 50-day simple moving average of $2.90 and a 200 day simple moving average of $8.76. And in between, it wasn’t a whole lot calmer. What Is Insider Buying? Scan for strong stocks. The Zacks rating relies solely on a company's changing earnings picture. If you’re ready to start capitalizing on this massive boom, legendary crypto investor Matt McCall just released a new free report, “3 Cryptos to Beat Bitcoin.”, Start Your Risk-Free Trial Subscription Here, Timing key in consulting deal between FirstEnergy, regulator, You Must Recognize Your Own Achievements First Before Expecting Others To, The Latest: Paris may face new lockdown as ICUs fill up, 'Big burden' for schools trying to give kids internet access, The Latest: Pakistan imposes partial lockdown in some areas, Once a virus epicenter, Los Angeles set to reopen - partly, Three Mall Retailers For Your Reopening Watchlist, 3 Growth Stocks with Above Market Dividend Yields, 3 Best Stocks to Buy That You’ve Probably Never Heard Of, Ferroglobe Will Get a Big Lift From Demand For Silcon Wafers, Blue Bird Stock is a Dual Tailwinds EV and Re-Opening Play, Nautilus Stock is a Pullback Buying Opportunity Here, The Launch of Truforma Should Send Zomedica to An All-Time High, Defi Markets Pause But New Highs Are In Sight, 7 Stocks That Cathie Wood is Buying And You Should Too, 7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future, 7 Undervalued Stocks That Deserve More Attention, 7 Semiconductor Stocks Set to Gain From the Chip Shortage, 7 Great Dividend Stocks to Buy For a Comfortable Retirement, 7 Penny Stocks That Don’t Care About Robinhood, 7 Hotel Stocks Just Waiting For the Vaccine, 7 Stocks to Watch When Student Debt Forgiveness Gets Passed, 7 Healthcare Stocks Delivering Innovation in 2021, 7 Lithium Stocks That Will Power the Electric Vehicle Boom, Here’s Where Churchill Capital IV Corp (NYSE: CCIV) Stock Can Bottom, 3 Low-Volatility Dow Jones Stocks to Buy Now, Anheuser-Busch Inbev Stock is a Must Own Re-Opening Play, Here’s Where the Nasdaq 100 (QQQ) Can Go From Here, Buy DocuSign Stock Because the World Has Changed Forever, Green Power Motor Stock Is A Perfect Play On EV, Receive Analysts' Upgrades and Downgrades Daily. Pinterest. See what's happening in the market right now with MarketBeat's real-time news feed. This stock may move very much during a day (volatility) and with a very large prediction interval from the Bollinger Band this stock is considered to be "very high risk". Akebia Therapeutics holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. WhatsApp. Many brokerage firms have already submitted their reports for AKBA stocks, with Needham repeating the rating for AKBA by listing it as a “Buy.” The predicted price for AKBA in the upcoming period, according to Needham is $15 based on the research report published on November 14th of the previous year 2019. Please read the full disclaimer here. Akebia Therapeutics (NASDAQ:AKBA) was downgraded by investment analysts at BidaskClub from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Wednesday, BidAskClub reports. For the last week, the stock has had a daily average volatility of 5.68%. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. HC Wainwright is very positive to AKBA and gave it a "Buy" rating on March 08, 2021. Learn about AKBA (XNAS) with our data and independent analysis including price, star rating, valuation, dividends, and financials. Akebia Therapeutics currently has 1 sell rating, 2 hold ratings and 4 buy ratings from Wall Street analysts. As of 2021 March 10, Wednesday current price of AKBA stock is 3.410$ and our data indicates that the asset price has been stagnating for the past 1 year (or since its inception).. Akebia Therapeutics, Inc. has been showing a declining tendency so we believe that similar market segments were mildly popular in the given time frame. AKBA Stock Analysis - [Full Report] Free Signup: Advanced stock screener. Learn more. Akebia Therapeutics (AKBA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal. This might drive the stock higher in the near term. AKBA -- USA Stock USD 3.00 0.11 3.54% The current analyst and expert consensus on Akebia Therapeutics is Buy , with 0 strong sell and 4 strong buy opinions. Your losses are our losses too. Twitter. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Akebia Therapeutics (NASDAQ:AKBA) was downgraded by investment analysts at BidaskClub from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Wednesday, BidAskClub reports. Further fall is indicated until a new bottom pivot has been found. After each calculation, the program assigns a buy, sell or hold value for each study, depending on where the price lies in reference to the common interpretation of the study. Find out if you should buy AKBA stock. Specifically, 8 analysts have assigned AKBA a recommendation rating as follows: 1 rate it as a Hold; 6 advise Buy while none analyst(s) assign an Outperform rating. During the last day, the stock moved $0.0900 between high and low, or 2.51%. View our full suite of financial calendars and market data tables, all for free. Our Accessibility Statement This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.This signal is rare and, in most cases, gives substantial returns. "StockInvest.us" is a research service that provides financial data and technical analysis of publicly traded stocks. Free Signup: Equities research analysts at Cantor Fitzgerald initiated coverage on shares of Akebia Therapeutics (NASDAQ:AKBA) in a research note issued to investors on Monday, The Fly reports. AKBA Buy or Sell? Private Advisor Group LLC bought a new stake in Akebia Therapeutics during the 2nd quarter worth approximately $25,000. Barchart Opinions are not a recommendation to buy or sell a security. I’m not trying to trip you up or send you down the rabbit hole on a secret speculative stock. A sell signal was issued from a pivot top point on Monday, February 08, 2021, and so far it has fallen -28.66%. Support: $3.47, Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor (HIF) biology for patients with kidney disease. Mizuho cut their price target on Akebia Therapeutics from $17.00 to $6.00 and set a "buy" rating for the company in a report on Friday, September 4th. What's Happening With Akebia Therapeutics Inc Stock Today? The firm set an "overweight" rating and a $8.00 price target on the biopharmaceutical company's stock. Akebia Therapeutics presently has an average rating of "Buy" and an average price target of $9.75. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Akebia Therapeutics Inc stock has fallen -24.49% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy.InvestorsObserver’s proprietary ranking system, gives AKBA stock a score of 73 out of a possible 100.. That rank is influenced by a short-term technical score of 80. Akebia Therapeutics (NASDAQ:AKBA) last posted its quarterly earnings data on Monday, August 10th. On the last day, the trading volume fell by -570 thousand shares and in total, 3 million shares were bought and sold for approximately $12.35 million. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.02. 7 analysts offering their recommendations for the stock have an average rating of 2.20, where 2 rate it as a Hold and 0 think it is a “Overweight”. The price has fallen in 6 of the last 10 days, but is still up by 4.34% over the past 2 weeks. Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. In last trading session, Akebia Therapeutics, Inc. (NASDAQ:AKBA) saw 4,602,567 shares changing hands with its beta currently measuring 1.81. This allows you to compare stocks extensively and in more detail than the common buy/hold/sell ratings. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 The AKBA stock forecast is provided by MarketClub with their Trade Triangle system. Finally, Valeo Financial Advisors LLC boosted its position in Akebia Therapeutics by 10.7% in the 2nd quarter. Out of . Most investors know that it is quite permissible for company leaders, such as directors of the board, to buy and sell stock in the company. Akebia Therapeutics (AKBA) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day! What Is Insider Buying? AKBA has been the subject of several other research reports. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. And that’s what I’m trying to do in this special presentation. And once you get to Christmas, it means that the end of the year is just a week away. Akebia Therapeutics (AKBA) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Analyst recommendations provided by FactSet shows that the consensus forecast for Akebia Therapeutics Inc. (AKBA) is a “Overweight”. BTIG Research cut their price target on Akebia Therapeutics from $26.00 to $6.00 and set a "buy" rating for the company in a report on Friday, September 4th. You can opt out at any time. Institutional investors and hedge funds own 76.75% of the company's stock. Facebook. Fundamental company data provided by Zacks Investment Research. Use the Zacks Rank and Style Scores to find out is AKBA is right for your portfolio. Macquarie Group Ltd. bought a new position in Akebia Therapeutics in the 2nd quarter valued at $60,000. Price: $3.61 No stop-loss is set. Resistance: $3.71 MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Akebia Therapeutics had a negative return on equity of 55.64% and a negative net margin of 113.35%. This story was reviewed by MarketBeat's editorial team prior to publication. Our recommended stop-loss: AKBA has been the subject of several other research reports. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). My advice to you is to keep it simple. So before you buy or sell Akebia Therapeutics, Inc. (NASDAQ:AKBA), you may well want to know whether insiders have been buying or selling. I’m looking at buying into companies that appear to be good buys as the economy recovers. Identify stocks that meet your criteria using seven unique stock screeners. You can buy or sell AKBA and other stocks, options, and ETFs commission-free! Finally, Needham & Company LLC assumed coverage on Akebia Therapeutics in a report on Tuesday, August 11th. Find out now with a free analysis on Akebia Therapeutics. The Akebia Therapeutics stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term moving average at $3.90. Given the current short-term trend, the stock is expected to rise 27.47% during the next 3 months and, with a 90% probability hold a price between $4.35 and $7.03 at the end of this 3-month period. Furthermore, there is currently a sell signal from the 3 months Moving Average Convergence Divergence (MACD). The predicted opening price is based on yesterday's movements between high, low, and the closing price. But whether you’re facing a decision on where to allocate IRA contributions or just looking to spend some time this holiday season rebalancing your portfolio, you may be wondering what stocks to buy in January of next year. Terms of Use and Privacy Policy. By using the site you agree and are held AKBA Stock Forecast - Is AKBA a buy or sell?